Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 5 mg (equivalent: memantine, qty 4.15 mg) - tablet, film coated - excipient ingredients: purified talc; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 5 mg (equivalent: memantine, qty 4.15 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; purified talc; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 15 mg (equivalent: memantine, qty 12.46 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; purified talc; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 15 mg (equivalent: memantine, qty 12.46 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; purified talc; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 20 mg (equivalent: memantine, qty 16.62 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; purified talc; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 10 mg (equivalent: memantine, qty 8.31 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 20 mg (equivalent: memantine, qty 16.62 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; purified talc; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 10 mg (equivalent: memantine, qty 8.31 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; purified talc; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 2 mg in 1 ml - memantine hydrochloride solution is indicated for the treatment of moderate to severe dementia of the alzheimer's type. memantine hydrochloride solution is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. teratogenic effects pregnancy category b there are no adequate and well-controlled studies of memantine in pregnant women. memantine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [mrhd] on a mg/m 2 basis). slight maternal toxicity, decreased pup weights and an increased incidence of non-ossified cervical verte

United States - English - NLM (National Library of Medicine)

lannett company, inc. - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 2 mg in 1 ml - memantine hydrochloride is indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. pregnancy category b there are no adequate and well-controlled studies of memantine in pregnant women. memantine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [mrhd] on a mg/m2 basis). slight maternal toxicity, decreased pup weights and an increased incidence of non-ossified cervical vertebrae were seen at an oral dose of 18 mg/kg/day in a study in which rats were given oral memantine beginning pre-mating a